CHP
RNAC icon

Cable Hill Partners’s Cartesian Therapeutics RNAC Stock Holding History

Cable Hill Partners’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-33
Closed -$10K – 917
2018
Q1 		$10K Hold
33
– – ﹤0.01% 492
2017
Q4 		$11K Buy
+33
New +$14.4K ﹤0.01% 554

Other funds holding RNAC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cable Hill Partners's RNAC Position: Q2 2018 in Review

Cable Hill Partners sold out of Cartesian Therapeutics (RNAC) in Q2 2018, closing a stake of 33 shares — an estimated $10K sold.

Cable Hill Partners first reported a position in RNAC in Q4 2017 and held it in 2 quarters. The position peaked at $11K in Q4 2017. 57 funds tracked by Wall St. Rank hold RNAC as of Q2 2018.

  • Cable Hill Partners reported no remaining Cartesian Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Cable Hill Partners sold 33 Cartesian Therapeutics shares in Q2 2018, an estimated $10K.
  • Cable Hill Partners first reported a position in Cartesian Therapeutics in Q4 2017 and held it in 2 quarters.
  • Cable Hill Partners's Cartesian Therapeutics position peaked at $11K in Q4 2017.
  • 57 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2018.

Based on Cable Hill Partners's 13F filing for Q2 2018, filed 3 Aug 2018.